Natco Pharma receives EIR from US FDA for Visakhapatnam manufacturing plant

The USFDA classified its August inspection as Voluntary Action Indicated (VAI), meaning the company must address the observations but faces no planned regulatory action. The development comes after Natco reported a 61% year-on-year decline in Q2 net profit.

Leave a Reply

Your email address will not be published. Required fields are marked *